Targeting HIF2α/AGR1 is considered as a novel treatment strategy for PAH, and Arg1 overexpression has been reported to be positively correlated with the viability and invasion ability of hepatocellular carcinoma cells (You et al., 2018; Macias et al., 2021). This evidence concerns the gene TXNDC12 and pulmonary arterial hypertension.